Breaking Down Evolus: 8 Analysts Share Their Views

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Evolus EOLS in the last three months.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

In the assessment of 12-month price targets, analysts unveil insights for Evolus, presenting an average target of $24.25, a high estimate of $27.00, and a low estimate of $22.00. This current average has increased by 2.67% from the previous average price target of $23.62.

Breaking Down Analyst Ratings: A Detailed Examination

An in-depth analysis of recent analyst actions unveils how financial experts perceive Evolus. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

| Analyst | Analyst Firm | Action Taken | Rating |Current Price Target| Prior Price Target | |--------------------|--------------------|---------------|---------------|--------------------|--------------------| |Serge Belanger |Needham |Maintains |Buy | $22.00|$22.00 | |Balaji Prasad |Barclays |Raises |Overweight | $25.00|$22.00 | |Douglas Tsao |HC Wainwright & Co. |Maintains |Buy | $27.00|$27.00 | |Serge Belanger |Needham |Maintains |Buy | $22.00|$22.00 | |Douglas Tsao |HC Wainwright & Co. |Maintains |Buy | $27.00|$27.00 | |Balaji Prasad |Barclays |Raises |Overweight | $22.00|$20.00 | |Douglas Tsao |HC Wainwright & Co. |Maintains |Buy | $27.00|$27.00 | |Serge Belanger |Needham |Maintains |Buy | $22.00|$22.00 |

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Evolus. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Evolus compared to the broader market.
• Price Targets: Delving into movements, analysts provide estimates for the future value of Evolus's stock. This analysis reveals shifts in analysts' expectations over time.

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Evolus's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on Evolus analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Get to Know Evolus Better

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Evolus's Economic Impact: An Analysis

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: Over the 3M period, Evolus showcased positive performance, achieving a revenue growth rate of 29.42% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: Evolus's net margin excels beyond industry benchmarks, reaching -8.6%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -119.02%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): Evolus's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -2.94%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Evolus's debt-to-equity ratio surpasses industry norms, standing at 23.54. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

The Basics of Analyst Ratings

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.